This randomised trial was designed to compare two groups treated with different G-CSF administration schedules with a third group receiving no G-CSF, after autologous peripheral blood stem cell transplantation (APBSCT). Children and adults with haematological malignancies or solid tumours were randomly assigned to receive either 150 lg/m 2 /day of Lenograstim starting on day 1 (G1) or on day 5 (G5) post APBSCT, or no Lenograstim (G0). Randomisation was stratified according to the conditioning regimen (Busulfan vs TBI vs no Busulfan and no TBI) and the graft CD 34 þ cell count. A total of 240 patients were randomised; 239 were evaluable. All three patient groups were comparable. Median duration of neutropenia was 9 days (4-40), and 10 days (5-15) in the G1 and G5 groups, respectively, significantly shorter than in the G0 group, 13 days (7-36) (Po0.0001). No difference was observed in the duration of thrombocytopenia, transfusion support and extra-haematological complications. The duration of post transplant hospitalisation was significantly shorter in adults who received G-CSF. Clinical and cost arguments favour the initiation of G-CSF on day 5 in adults. The same policy could be applied in children given that clinical management is easier and costs are similar.
cost effectiveness; randomised study Since the mid 1990s, autologous peripheral blood stem cells (APBSC) have been used extensively to reconstitute haematopoiesis. In terms of haematological recovery, APBSC have been proven superior to autologous bone marrow transplantation (ABMT) resulting in a shorter duration of neutropenia and thrombocytopenia.
1 Although G-CSF is clearly beneficial after ABMT, affording a shorter duration of neutropenia, its role after APBSC transplantation (APBSCT) remains to be defined. The aim of this study was to evaluate whether G-CSF would be beneficial after APBSCT and, if so, to define its optimum schedule of administration. A randomised controlled trial comparing two groups with different G-CSF administration schedules to a third group without G-CSF was thus undertaken in patients treated for malignancies with HDC and PBSCT by the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Patients and methods

Patients
Patients of any age with a solid tumour or a haematological malignancy, who were to receive a single course of highdose chemotherapy (HDC) combined or not with total body irradiation (TBI) and APBSCT in a SFGM-TC transplantation unit, were eligible for inclusion in this study. Patients in whom lenograstim was contraindicated and who required an ex vivo manipulated autograft were not included. Written informed consent was required of all eligible patients or of the parents of eligible children. This protocol was approved by the Kremlin-Biceˆtre Ethics Committee, France.
Methods
Study schedule. Centralised computerised randomisation was performed by fax on day 1 of the conditioning regimen. The three treatment groups consisted respectively of patients receiving no G-CSF (G0 group), lenograstim (Granocyte s Chugai-Aventis) at a dose of 150 mg/m 2 starting on day 1 post APBSCT (G1 group) or starting on day 5 post APBSCT (G5 group). Lenograstim administration was stopped when more than 0.5 Â 10 9 /l neutrophils were obtained from two blood cell counts, 48-h apart.
No other haematopoietic growth factors were allowed during the trial. G-CSF could be administered in the G0 group if granulocytopenia (o0.5 Â 10 9 /l PNN) persisted after day 15 post APBSCT.
Randomisation was stratified by centre and, given the particular haematological toxicity of busulfan and TBI, by the type of conditioning regimen planned (TBI, and HDC with or without Busulfan), and by the number of CD 34 þ cells collected (X3 Â 10 6 CD 34 þ cells/kg/o3 Â 10 6 CD 34 þ cells/kg).
The main clinical end point was the duration of granulocytopenia (o0.5 Â 10 9 /l PNN). Other clinical criteria were the duration of thrombocytopenia (o20 Â 10 9 /l and o50 Â 10 9 /l), duration of febrile granulocytopenia, number of infectious complications and duration of hospitalisation.
Cost-effectiveness study
This was performed from the point of view of a French hospital. A separate analysis was performed in adults and children because patient care requirements are organised differently. The cost analysis was restricted to direct medical costs. The following parameters were recorded for each patient: days of hospitalisation, transfusions, G-CSF, anti-infectious drugs and IV nutrition. Monetary valuation was performed in 1999 French francs. The per diem room rate for conventional hospitalisation (staff, non medical expenses and overheads) was calculated using analytical accounting on the hypothesis that the two departments (one paediatric and one adult transplantation unit) were fully occupied. French sales prices before negotiation were used for the valuation of drugs, the French health care system tariff for the laboratory and diagnostic tests, and official French prices for transfusions. Results are presented in Euros. A sensitivity analysis was performed for the G-CSF sale price and per diem room cost.
Statistical analysis
G-CSF had previously been administered according to the G1 schedule. The mean duration of neutropenia previously observed in this setting was 8 days (SD 3 days). 1 It was thus estimated that a minimum of 70 patients per group would be necessary to demonstrate a minimum reduction of 2 days for granulocytopenia in the lenograstim groups (two-tailed test, a ¼ 0.05, b ¼ 0.10) compared to the no Lenograstim group (G0). Analyses were carried out on an intent-to-treat basis. Differences between groups were evaluated by the chi-square test or Fisher's exact test for categorical variables and Student's t-test for continuous variables (two-sided tests). Owing to the non-normality of cost distribution, costs were compared by the Wilcoxon nonparametric test.
All analyses of clinical end points were adjusted for centre and conditioning regimen.
Patient management PBSC collection. PBSC were mobilised either in haematological steady state with G-CSF (10 mg/kg/day) or with chemotherapy and G-CSF (5 mg/kg/day). The number of cytaphereses performed was adjusted to the targeted number of CD 34 þ cells to be collected.
Follow-up. Daily surveillance began on the first day of hospitalisation for HDC and was continued throughout the hospital stay. All patients were fitted with right atrial catheters on admission and nursed in laminar air flow single rooms. They received parenteral nutrition and broadspectrum antibiotics when indicated. Platelet infusions and red cell concentrates were used to maintain a platelet count 420 Â 10 9 /l and haemoglobin 470 g/l. All blood products were irradiated at a dose of 25 Gy before transfusion. All extra-haematological complications were recorded according to the criteria reported by Bearman et al.
2
Conditioning regimen and transplantation. The conditioning regimen consisted of a combination of HDC with, or without TBI. It was in line with the protocols currently developed by the national tumour committees for each malignancy. Transplantation was performed 1-2 days after the end of the conditioning regimen.
Results
A total of 240 patients were randomised in 23 French transplantation units between September 1998 and November 1999. One patient in the G0 group did not receive HDC and APBSCT. Thus, the analysis presented here includes 239 patients, 80 in the G1 and G5 groups and 79 in the G0 group. Table 1 presents the baseline characteristics of the three groups. HDC7TBI was most often indicated for lymphoma (41%) and myeloma (16%) in adults, and for neuroblastoma and Ewing's tumour (19%) in children. Before entering the trial, all but one patient had been treated with conventional combination chemotherapy according to a specific protocol. They had received a median number of six drugs (range 1-12) and a median number of seven courses (range 1-24) before conditioning and APBSCT. A total of 60 of them had previously received local radiotherapy. As a result of previous treatment, 87 (36.4%) were in complete remission (CR) and 16 (6%) had progressive disease at the time of the transplantation. Clinical status at the time of the graft did not differ significantly between the three groups. Myeloablative treatment before APBSCT consisted of a busulfan-containing regimen in 27% of the patients, a TBI-containing regimen in 17% of them and other combinations in 56%.
A median number of two leukaphereses (range 1-9) was performed to harvest the graft and was similar in the three groups. Most patients (86.6%) were grafted with more than 3 Â 10 6 /kg CD 34 þ cells. The median number of grafted CD 34 þ cells was 45 Â 10 6 /kg and was similar in the three groups (Table 2) . Few protocol violations occurred. In the G0 group, no patient received G-CSF before day 15. It was administered on day 17, day 18 and day 29 in three patients with persistent granulocytopenia. In the G1 group, G-CSF administration was delayed in two patients (days 2 and 5). In the G5 group, three protocol violations occurred: G-CSF was started on days 4, 7 and 8. As shown in Table 3 , the median duration of granulocytopenia (o0.5 10 9 /l) was significantly shortened by about 3 days in the two groups receiving G-CSF as compared to the G0 group (Po0.0001). The incidence of secondary granulocytopenia was 1, 8 and 6% in the G0, G1 and G5 group, respectively, and was not statistically different (P ¼ 0.1). Conversely, the duration of neutropenia was significantly different according to the conditioning regimen, 12.5 days (range 7-31), 8 days (range 4-36) and 10 days (range 4-34) in the TBI group, Busulfan group and no-TBI-no-busulfan group, respectively (Po0.00001). The shorter duration of neutropenia after G-CSF was similar in the three groups. The duration of neutropenia was significantly longer when the CD 34 þ cell count was o3 Â 10 6 /kg, 11.5 days (range 6-33) than when it was 43 Â 10 6 /kg, 10 days (range 4-36) (P ¼ 0.02). G-CSF administration impacted on the duration of neutropenia whatever the number of CD 34 þ cells infused. No difference in the duration of thrombocytopenia o20 Â 10 9 /l or 50 Â 10 9 /l was observed between the three groups (Table 3 ) even in patients who received o3 Â 10 6 / CD 34 þ cells/kg. As shown in Table 3 , no difference was observed between the three groups in transfusion support. The median duration of Lenograstim administration was 11 (range 4-5) and 8 days (range 4-34) in the G1 and G5 group, respectively; the difference was statistically significant (Po0.0005).
In all, 224 patients (94%) experienced at least one febrile episode, a microorganism was identified in 43 patients (19% of the febrile patients), 16, 11 and 16 in the G0, G1 and G5 group, respectively (NS). As shown in Table 3 , no difference in the duration of febrile granulocytopenia was observed according to the G-CSF administration schedule. Similarly, no difference was observed between the three groups in terms of extra-haematological complications (Table 3) . However, the incidence of mucositis and hepatic veno-occlusive disease (HVOD) was significantly higher in children (88%) when compared to adults (61%) (P ¼ 0.001). This toxicity was related to the more frequent administration of Busulfan in the paediatric HDC regimens (80%) compared to their adult counterparts (12%). The onset of one of these complications significantly prolonged post transplant hospitalisation in adults 15 (3-53) vs 17 days (8-73), (P ¼ 0.0005) and in children 17 (14-35) vs 24 (15-48) days (P ¼ 0.05), although the number of children who did not develop other mucositis or HVOD was low (n ¼ 6). Median duration of hospitalisation was 25 days in the G1 and G5 groups, compared to 27 days in the G0 group. This difference was not statistically significant (P ¼ 0.08). Table 1 Comparability of G0, G1 and G5 groups The duration of post transplant hospitalisation was 20 (3-48), 16 (8-53) and 16 (11-73) days in the G0, G1 and G5 group, respectively. The difference was statistically significant between G0 and G1 (P ¼ 0.0009) and G0 and G5 (P ¼ 0.0005) and was mostly observed in adults. In spite of the occurrence of visceral toxicity, G-CSF significantly shortened the duration of post transplant hospitalisation: 19 (14-40) in the G0 group vs 16 (8-73) days in the two pooled G-CSF groups (P ¼ 0.001). Conversely, hospitalisation was not shortened by G-CSF administration in children who experienced mucositis or HVOD: 25 (16-48) and 24 (15-43) days.
A cost analysis was performed on 52 children and 187 adults. One adult who died just after transplantation from multiorgan failure was excluded from the analysis. Results are presented in Table 4 for children and in Table 5 for adults. The total costs in adults and children were not significantly different between the three treatment groups. Hospitalisation incurred the main cost especially in children, whatever the treatment group. In children, G-CSF represented 6 and 4% of the total post transplant cost in the G1 and G5 groups, respectively. In adults, G-CSF represented 12 and 10% of the total post transplant cost in the G1 and G5 groups, respectively. In adults, the reduced hospitalisation costs resulting from G-CSF administration did not completely balance out the cost of G-CSF administration. Results were robust in the univariate sensitivity analysis in children and adults. In the adult population, multivariate sensitivity analysis of the G-CSF sale price and per diem room rate showed that, using realistic assumptions (for example, negotiated reduction of 17% of G-CSF price and an increase to 610 Euros per diem room rate), the total cost for G5 becomes significantly lower than that for G0. No differences were found between the G1 and G0 groups using realistic assumptions.
Discussion
APBSC is now commonly used as stem cell support in adults and children after myeloablative treatment, because it has been demonstrated to shorten the duration of neutropenia, thrombocytopenia, hospitalisation and costs of therapy compared to BMT. Table 4 Costs of treatment for children (mean (standard error) in Euros) This randomised trial in a large series of patients aimed to compare two groups of patients with different G-CSF administration schedules (early on day 1 and delayed on day 5) to a third group without G-CSF. A dose of 150 mg/m 2 was administered, since higher doses have not been demonstrated to be beneficial in a randomised study. 3 Stratification, performed according to the conditioning regimen, allowed a similar distribution of underlying malignancies in the three groups and no age variation, although adults and children were included. Stratification was also performed according to the CD 34 þ cell content since it has been demonstrated to have a significant impact on haematological recovery. 4 The present trial demonstrated that the administration of G-CSF is associated with a significantly shorter duration of neutropenia. This effect was observed whatever be the number of CD 34 þ cells infused. Bensinger et al 4 have already demonstrated a strong impact of the number of CD 34 þ cells on the duration of neutropenia in a retrospective study and this is confirmed by our study. We chose to stratify the study according to the graft CD 34 þ cell content, with a 3 Â 10 6 CD 34 cells/kg cutoff, based on the study by Faucher et al. 5 They demonstrated that the only predictive factor for both granulocyte and platelet recovery was the number of CD 34 þ cells reinfused and recommended the reinfusion of a minimal number of 3 Â 10 6 CD 34 þ cells. In the study by Bensinger et al, impaired thrombocytopenia recovery was observed in patients receiving myeloid growth factors when the graft CD 34 þ cell content was less than 5 Â 10 6 /kg. We did not observe a similar effect of G-CSF on the duration of thrombocytopenia with a different CD 34 þ cutoff. Although the duration of neutropenia was significantly different according to the myeloablative treatment, with a significantly longer duration for patients conditioned with the TBI-containing regimen, the impact of G-CSF was observed in all groups. As already observed in most studies, the shorter duration of neutropenia had no impact on incidence and duration of fever and documented infections. However, a randomised study comparing the administration of Lenograstim s to a placebo displayed a decrease of microbiologically defined infections. 6 In adults, the duration of post transplant hospitalisation was significantly shortened when G-CSF was administered, even when patients experienced visceral toxicities. Using realistic hypotheses of per diem hospitalisation costs and the price of G-CSF, the cost of G-CSF is offset by the shorter duration of hospitalisation that occurred. In children, because of the high incidence of mucositis and HVOD, and because of the paediatric management of these toxicities, we found that G-CSF had no impact on the post transplant duration of hospitalisation or on costs. However, clinical practice is in favour of the initiation of G-CSF on day 5 to facilitate the management of these toxicities. HVOD requiring hydration restriction is easier to manage when patients are no longer neutropenic and do not need antibiotics. Several randomised studies have demonstrated a significant impact of G-CSF administration on the duration neutropenia after APBSCT when G-CSF was initiated on day 1. [7] [8] [9] [10] The study reported by Mc Quacker et al 9 was the only one to evaluate the economic impact and was in favour of G-CSF administration. Other randomised studies comparing the initiation of G-CSF administration on day 5 with no G-CSF demonstrated a shorter duration of neutropenia after G-CSF. 11, 12 Both studies evaluated the costs, but only the study reported by Lee in 23 patients showed a favourable economic impact of G-CSF administration. Faucher et al compared two G-CSF administration schedules (day 1 and day 6) in 35 patients. No difference was observed in the duration of neutropenia between the two groups but a cost evaluation was not performed. 13 The present study is the largest evaluating the impact of G-CSF after APBSCT and comparing early (day 1) and delayed (day 5) G-CSF administration schedules vs no G-CSF together with an economic evaluation.
In conclusion, this randomised clinical trial demonstrates that the duration of granulocytopenia is shortened when G-CSF is administered after APBSCT. Moreover, the duration of post transplant hospitalisation was significantly shorter in adults, with no difference according to the day of its initiation (day 1 or day 5). No impact of G-CSF administration could be demonstrated in children because of the high incidence of visceral toxicities in this population. Overall costs would be lower if G-CSF is initiated on day 5 in adults. Clinical and economic arguments favour the initiation of G-CSF on day 5 post APBSCT in adults. The same policy could be applied to children given that costs are similar and visceral toxicity is easier to manage when patients are not granulocytopenic.
